Highlights

  • Third quarter total Revenue rose 29% to USD 1,313 million on higher COVID Vaccine sales in international markets.
  • Net income reached USD 162 million, or USD 0.38 per diluted share, against a net loss of USD 200 million.
  • Cash, cash equivalents and investments totaled USD 7,976 million after a USD 3.0 billion convertible notes issuance in September.
  • Management raised its 2026 revenue growth framework to 15% to 25%, up from a prior outlook of up to 10%.

Moderna, Inc. (NASDAQ:MRNA) shares were trading near their 52-week high at USD 254.19 on November 6, 2026, up 5.27%. The mRNA medicines company received U.S. approval for its mFLUSIVA influenza vaccine in August, issued USD 3.0 billion of convertible notes in September, and reported third quarter results on November 6 with a raised 2026 revenue growth outlook.

Based in Cambridge, Massachusetts, Moderna is a Delaware corporation that describes itself as a biotechnology company advancing a new class of medicines made of messenger RNA. It has five approved products: the COVID vaccines Spikevax and mNEXSPIKE, the RSV vaccine mRESVIA, the combination flu and COVID vaccine mCOMBRIAX, and the influenza vaccine mFLUSIVA. Its pipeline spans infectious disease, oncology and rare disease, including intismeran autogene, developed jointly with Merck. Moderna has a market Capitalization of USD 101.48 billion, and its fiscal year ends December 31.

Third Quarter Results and Product Mix

Total revenue was USD 1,313 million against USD 1,016 million a year earlier. Net product sales rose 31% to USD 1,273 million, led by COVID vaccines at USD 1,244 million. Europe sales climbed to USD 314 million from USD 16 million on deliveries under long-term government partnerships. U.S. sales eased to USD 771 million from USD 782 million, and mFLUSIVA sales were immaterial.

Cost of sales rose to USD 318 million from USD 207 million, including USD 54 million of inventory write-downs. Research and Development expense fell 27% to USD 583 million. Income from operations was USD 130 million against an operating loss of USD 260 million.

For the nine months, revenue was USD 1,847 million against USD 1,266 million, yet Moderna posted a net loss of USD 1,963 million, or USD 4.93 per share, against USD 5.15. Nine month cost of sales included USD 890 million of Royalty expense tied to the Arbutus and Genevant settlement.

Pipeline and Regulatory Progress

The FDA approved mFLUSIVA in August for adults 50 and older, with Accelerated Approval for adults 65 and older, and sales began in September.

In the Phase 3 INTerpath-001 melanoma trial, intismeran autogene combined with Merck's KEYTRUDA met its primary endpoint of recurrence-free survival. The combination cut the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% against KEYTRUDA alone. Overall survival data are not yet mature.

Not every program advanced. The Phase 3 norovirus vaccine trial missed the statistical criteria for early success at its interim analysis, and Moderna will not enroll another cohort this season. The combination flu and COVID vaccine awaits FDA guidance on a U.S. refiling.

Balance Sheet, Financing and Legal Matters

Cash, cash equivalents and investments totaled USD 7,976 million, USD 159 million below the year-end 2025 level. The September issuance of 0.00% convertible senior notes due 2032 raised USD 3.0 billion, leaving net proceeds of USD 2.6 billion after USD 329 million of capped call costs.

Legal exposure remains open. Moderna paid a USD 950 million lump sum in July under the Arbutus and Genevant settlement and has appealed a related court decision. Depending on the outcome of the Federal Circuit appeal, an additional payment of up to USD 1.3 billion is payable, and Moderna has recorded no accrual for it. Patent complaints from Northwestern University, Bayer and Monsanto, BioNTech, and CureVac are pending.

Outlook

Management raised its 2026 revenue growth framework to 15% to 25% from up to 10%. It cut its research and development estimate by USD 200 million to USD 2.7 billion and expects cash costs of USD 3.8 billion and year-end cash and investments of USD 8.1 billion to USD 8.3 billion.